-
Merck & Co. reported a 4th quarter profit of $1.64 billion, or 78 cents per share, compared to a loss of $1.63 billion a year ago, due to lawsuits over Vioxx (rofecoxib).The sales for Fosamax (alendronate sodium) were down 60%, to $318 million, the sales of blood pressure medicines Cozaar (losartan potassium) and Hyzaar (losartan potassium and hydrochlorothiazide) were down as well, at $881 millio
제약단신
메디칼라이터팀
2009.02.05 00:00
-
Joint research between the Northwestern University in the US and the University of Rio de Janeiro in Brazil studied the effects of insulin on proteins called ADDLs, which accumulate in the brains of Alzheimer"s patients and are damaging. In the course of the research project neurons from the hippocampus, were treated with insulin and a drug called rosiglitazone, given to type II diabetics to incr
제약단신
메디칼라이터팀
2009.02.05 00:00
-
This one-day conference will provide a focused forum for individuals from pharmaceutical/biotech companies to discuss issues of relevance to Medical Science Liaison teams. Whether you are a Medical Science Liaison or a director of Medical Science Liaisons, this conference will provide a dynamic environment to interact with leaders in the field.February 19, Arlington, VA, USA
제약단신
메디칼라이터팀
2009.02.05 00:00
-
A study at the University of Southern California, published in the journal Blood, found that, in animals as well as in test tubes, certain anti-oxidant compounds of green tea blocked the effects of Takeda’s cancer drug Velcade (bortezomib) and its cancer cells destroying capacity. This evidence is contrary to previous optimism in the cancer research and patient communities over the curative potent
제약단신
메디칼라이터팀
2009.02.05 00:00
-
A FDA advisory committee will probably approve prasugrel (Effient) for preventing thrombosis in high-risk acute coronary syndrome patients who undergo percutaneous coronary intervention. The agency"s reviewers are firmly convinced of the effectiveness of the drug and its superiority over clopidogrel (Plavix). However, the drug has been shown to increase bleeding, particularly for elderly and Asia
제약단신
메디칼라이터팀
2009.02.04 00:00
-
Joint research between the Northwestern University in the US and the University of Rio de Janeiro in Brazil studied the effects of insulin on proteins called ADDLs, which accumulate in the brains of Alzheimer"s patients and are damaging. In the course of the research project neurons from the hippocampus, were treated with insulin and a drug called rosiglitazone, given to type II diabetics to incr
제약단신
메디칼라이터팀
2009.02.04 00:00
-
A study at the Arizona Alzheimer"s Consortium and Arizona State University, published in the February issue of Behavioral Neuroscience, found that rats injected with hydroxyfasudil (Fasudil) performed better on a maze that tested their learning and working memory than those given a placebo. In addition, the rats given higher doses of the drug did better than those given a lower dose. Fasudil has
제약단신
메디칼라이터팀
2009.02.04 00:00
-
According to an FDA research, to be published in this month issue of Pediatrics, are treatment-related hallucinations and other psychotic symptoms in children treated for attention deficit hyperactivity disorder (ADHD) more common than previously thought. The researchers identified more than 850 separate incidences of hallucinations and other psychotic episodes among children using Ritalin LA (met
제약단신
메디칼라이터팀
2009.02.04 00:00
-
BioGenes GmbH, a biotechnology company based in Berlin, Germany, specializing in antibody development, has been chosen as a partner of the EU funded research project cNEUPRO. cNEUPRO stands for Clinical Neuroproteomics of Neurodegenerative Diseases and unites nineteen biotech and bioinformatics’ companies as well as leading clinical and proteomic dementia research centers. The project will analyze
제약단신
메디칼라이터팀
2009.02.03 00:00
-
Research at the University of Tennessee Health Science Center, published in the Archives of Internal Medicine, Jan. 26, studied the fractures over 7.7 years of 300 users and 9,124 non-users of loop diuretics and analyzed data on baseline and 3 year bone mineral density, using the data on 133,855 postmenopausal women. The researchers concluded that the women using loop diuretics for more than 3 yea
제약단신
메디칼라이터팀
2009.02.03 00:00
-
The FDA has approved Gelnique (oxybutynin chloride), a gel produced by Watson Pharmaceuticals, to treat symptoms of an overactive bladder. The gel is applied daily to the thigh, abdomen, upper arm or shoulder. Its active ingredient oxybutin chloride is known as an oral drug, but as a gel is it is not metabolized by the liver, which reduces side-effects. During the 12-week trial, that included 789
제약단신
메디칼라이터팀
2009.02.03 00:00
-
Takeda Pharmaceuticals North America Inc. announced on Jan. 30 that the FDA approved Kapidex "delayed release capsules" (dexlansoprazole), a proton pump inhibitor, for the treatment of gastroesophageal reflux disease (GERD). In an 8 week trial, Kapidex showed an effectiveness similar to Takeda’s drug Prevacid (lansoprazole), which will lose its patent protection later this year.
제약단신
메디칼라이터팀
2009.02.03 00:00
-
Roche Holding made a new bid to buy Genentech Inc. Jan 30 by offering $86.50 per share -- $2.50 less than its previous offer, after failing to reach an agreement with its directors. The lower offer is an effort to speed up the deal and a reminder to Genentech shareholders that their shares would be selling for less without Roche’s bid in place. In reaction Genentech shares fell 3.4% to $2.86.
제약단신
메디칼라이터팀
2009.02.03 00:00
-
An external panel of medical experts, advising the FDA, recommended banning the drugs Darvon (propoxyphene, Xanodyne Pharmaceuticals and Qualitest/Vintage Pharmaceuticals) and Darvocet (propoxyphene napsylate and acetaminophen) on Jan 31, after Public Citizen sued the FDA in order to force a ban on the pain treatment. Public Citizen, a nonprofit consumer advocacy organization, cited data implicati
제약단신
메디칼라이터팀
2009.02.03 00:00
-
A study, published online in the Clinical Journal of the American Society of Nephrology, enrolled 230 chronic kidney disease patients with iron-deficiency anemia who were on dialysis to treatment with either two injections of 510 mg ferumoxytol within seven days or 200 mg oral iron daily for 21 days. The researchers found that after 35 days, patients treated with ferumoxytol had significantly grea
제약단신
메디칼라이터팀
2009.02.02 00:00
-
FDA 사전보고, "PPI 병용" 때문으로 추정 미국식품의약국(FDA)은 클로피도그렐(clopidogrel bisulfate, Plavix)에 대한 "얼리커뮤니케이션"을 발표, 일부 환자들에게서 효과가 미비하게 나타난다는 기존 보고들에 대한 추가연구를 진행할 계획이라고 밝혔다. 이번 추가연구는 제조사인 사노피-아벤티스(Sanofi-Aventis)사와 브리스톨-마이어스 스킵(Bristol-Myers Squibb)사와 함께 진행할 예정이다. FDA는 클로피도그렐은 혈전을 예방하는 항혈소판제제로 효과를 내기 전 체내에서 신진대사가 이뤄져야하는 약물이기 때문에 환자에 따른 클로피도그렐 대사능력의 차이와 프로톤펌프억제제(PPI)와 병용해 사용하는 경우에 가능성을 두고 있다. PPI의 경우 몇몇 연구들에서
제약단신
임세형 기자
2009.02.02 00:00
-
빈민 증가따라 공중보건 수요 늘 듯최신치료 편중 말고 예방의학 지원을WHO 보고서 경제에 피어오른 먹구름이 보건에도 그림자를 드리울 수 있다. 세계보건기구(WHO)는 "경제위기와 세계보건(Financial Crisis and Global Health)" 보고서를 통해 세계적인 경제위기의 여파가 극심한 지금이 보건상태를 유지하고 위기상황에 대비하기 위한 장기적인 시야가 필요한 시기라고 밝혔다. WHO는 보고서에서 경제위기가 일차적으로 식량과 기름값에서 나타나고 이로인해 1억명 이상이 가난해 질 것으로 전망했다. 특히 개발도상국들의 경우 가난으로 인해 감소하는 기부나 원조가 보건상황을 위태롭게 하고 있다고 설명했다. 연구기관과 하부구조가 취약한 만큼 보건상태에 극심한 영향이 나타난다는 것. 또한 작은
제약단신
김수미 기자
2009.02.02 00:00
-
낙태 관련 여성 사망률 감소 대책 제시미 산부인과학회 성명 미국산부인과학회(ACOG)가 성명서를 통해 저소득국가의 여성사망률 감소를 위해 미소프로스톨(misoprostol)의 사용을 국제적으로 확대해야 한다고 강조했다. ACOG는 저소득국가들에서 낙태와 유산으로 인한 여성사망률이 높다는 점을 지적하고 적절한 시기와 환경에서 의료서비스를 받는 것은 여전히 힘든 상황에서 안전하고 비싸지 않은 미소프로스톨을 낙태 후 의료서비스 제공과 여성사망률 감소를 위한 대책으로 제시했다. 낙태 후 여성의 건강관리를 위한 미소프로스톨의 복용전략은 미국공중보건협회(APHA), 미국응급피임학회(ASEC) 등에서 여러 번 제기된 바 있다. 미국식품의약국(FDA)에서도 미소프로스톨 복용을 통한 낙태에 대해서 7주 임신에서 3일
제약단신
김수미 기자
2009.02.02 00:00
-
FDA 첫 승인 올 여름부터 진행 배아줄기세포를 이용한 연구가 다음 단계로 들어가는 문고리를 잡았다. 미국식품의약국(FDA)은 게론(Geron)사의 "GRNOPC1" 연구를 승인, 세계최초로 인간배아세포에 기반을 둔 치료법에 대한 인체 임상연구를 올 여름부터 진행한다. 게론사의 오카마(Thomas B Okarma) 사장은 "이번 FDA의 승인은 의학 치료분야에서의 잠재적으로 새로운 장의 시작"이라며 이번 승인의 의의를 밝혔고 일부 전문가들은 인체 임상에 대한 안전성의 허들을 넘었다는 점 자체로도 의미가 있다고 말했다. 이 연구는 인간배아세포에서 추출한 희소돌기아교 전구세포(oligodendrocyte progenitor cells, OPC)를 직접 주입하는 방법으로 인체에 대한 안전성 확인을 일차종료점
제약단신
김수미 기자
2009.02.02 00:00
-
AstraZeneca announced on Jan 28 a decline in net profit of 1.4% to $1.25 billion in the 4th quarter, from $1.27 billion a year earlier. The company"s 4th quarter sales rose marginally to $8.19 billion from $8.17 billion. Sales revenues from cholesterol-lowering drug Crestor (rosuvastatin calcium) rose 23% to $987 million and sales from asthma drug Symbicort (budesonide and formoterol) increased 1
제약단신
메디칼라이터팀
2009.02.02 00:00